Study analysis · The New England journal of medicine · 2025
A weekly shot reversed liver inflammation in 63% of MASH patients — nearly double placebo — but it's not a cure and comes with gut side effects.
In a large trial, a weekly semaglutide injection helped about 29 more out of 100 people with a serious fatty liver disease clear liver inflammation without worsening scarring, compared with placebo.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like a big experiment where some people get a new medicine and some get a fake pill, and we compare them. Because the groups were chosen by chance and no one knew who got the real medicine, we can be very sure that the medicine caused the improvements in the liver. So we can say 'the medicine helps' not just 'it might help'.
What’s the bottom line?
This large randomized trial tested weekly semaglutide 2.4 mg in people with MASH, a serious fatty liver disease, and liver scarring. Over 72 weeks, semaglutide improved liver health more than placebo and led to more weight loss. Stomach and gut side effects were more common with semaglutide. The study also has published corrections/errata, so check the notices for updated information.
How strong is this study?
This study was very well done – it had many people, it was fair (random assignment), and both the patients and doctors were kept in the dark about who got the medicine. That means we can trust the results a lot. However, it's only part of a larger study, so we still need to see the final results to be completely sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
100 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=800)+19.6/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 588 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. As an individual RCT with narrow confidence intervals, this study can establish that semaglutide causes improvement in liver histology (resolution of steatohepatitis and fibrosis reduction) in the studied population. However, causation is limited to the specific population (MASH with fibrosis stage 2 or 3) and is based on an interim analysis at 72 weeks; final results may differ slightly.
No Conflicts
No conflicts of interest identified
No conflicts of interest declared or identified in the provided text.
The text is a scientific review article without any disclosure of conflicts of interest or funding sources. The analysis is based solely on the provided text.
Key takeaways
- 01
In people with MASH and liver scarring: hepatitis resolution without worse scarring occurred in 62.9% with semaglutide vs 34.3% with placebo (absolute difference 28.7 percentage points; about 29 more per 100 people).
- 02
Less scarring without worse hepatitis occurred in 36.8% vs 22.4% (absolute difference 14.4 percentage points; about 14 more per 100 people).
- 03
Both hepatitis resolution and less scarring occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points; about 16 more per 100 people).
- 04
Average weight change was -10.5% vs -2.0% (absolute difference 8.5 percentage points more weight loss).
- 05
Gastrointestinal side effects were more common with semaglutide.
- 06
These are absolute differences from the trial.
- 07
For every 100 patients treated for 72 weeks, about 29 more had hepatitis resolution, about 14 more had reduced liver scarring, and about 16 more had both, compared with placebo.
- 08
Average weight loss was about 8.5 percentage points greater with semaglutide.
- 09
Absolute risks were reported directly as percentages in the study, so no extra calculation was needed.
Surprising findings
- Bodily pain scores did not differ significantly between groups despite large weight loss.Weight loss often improves joint pain, especially in obesity-related osteoarthritis; here no significant difference at 72 weeks.
- Semaglutide improved fibrosis without worsening steatohepatitis in 36.8% vs 22.4%, but nearly two-thirds still did not achieve this.GLP-1 drugs are often hyped as miracle cures; here a majority still had persistent fibrosis.
- GI adverse events more common, but no increase in serious adverse events was reported.Common side effects are bothersome but not dangerous; safety profile consistent with GLP-1 class.
Practical takeaways
If you have MASH with fibrosis stage 2–3, ask your doctor about semaglutide 2.4 mg weekly as a potential treatment option.
Not everyone responds; 37.1% did not achieve steatohepatitis resolution; GI side effects common; long-term data pending.
High for 72-week histologic benefit; medium for long-term outcomes. confidenceDon't rely on semaglutide alone; lifestyle changes (diet, exercise) remain foundational for liver health and weight management.
Trial did not test semaglutide plus intensive lifestyle vs alone; placebo group also had some improvement.
High. confidenceMonitor for gastrointestinal side effects and discuss ways to manage them if starting semaglutide.
Side effects were more common but not more serious in this trial; real-world adherence may differ.
High. confidenceWhy this study matters
Semaglutide nearly doubled steatohepatitis resolution
At 72 weeks, 62.9% of semaglutide patients had resolution of steatohepatitis without worsening fibrosis vs 34.3% on placebo — an absolute difference of 28.7 percentage points (95% CI 21.1–36.2). That means about 29 more people per 100 benefited.
MASH can lead to cirrhosis and liver cancer; this is first phase 3 evidence that a GLP-1 drug can reverse key liver damage.
Fibrosis improvement without worsening inflammation
Reduction in liver fibrosis without worsening steatohepatitis occurred in 36.8% with semaglutide vs 22.4% placebo — absolute difference 14.4 percentage points (95% CI 7.5–21.3). About 14 more per 100 had less scarring.
Scarring is what drives long-term liver failure; showing improvement is a big deal.
Combined win: both inflammation and scarring improved
Combined resolution of steatohepatitis and reduction in fibrosis: 32.7% vs 16.1% — absolute difference 16.5 percentage points (95% CI 10.2–22.8). This doubled the placebo rate.
Shows semaglutide can hit two disease pathways at once.
Meaningful weight loss, but GI side effects
Mean weight change -10.5% with semaglutide vs -2.0% placebo (absolute difference -8.5 percentage points). GI adverse events (nausea, vomiting, diarrhea, constipation) were more common.
Weight loss likely contributes to liver benefit, but side effects are real.
Interim results from ongoing 240-week trial
This is a planned interim analysis at 72 weeks of 800 patients; the full trial runs 240 weeks. Industry funded by Novo Nordisk; several authors are employees. Published corrections/errata exist.
Long-term outcomes and safety are still pending; early results can change.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This large randomized trial tested weekly semaglutide 2.4 mg in people with MASH, a serious fatty liver disease, and liver scarring. Over 72 weeks, semaglutide improved liver health more than placebo and led to more weight loss. Stomach and gut side effects were more common with semaglutide. The study also has published corrections/errata, so check the notices for updated information.
Research results
In people with MASH and liver scarring: hepatitis resolution without worse scarring occurred in 62.9% with semaglutide vs 34.3% with placebo (absolute difference 28.7 percentage points; about 29 more per 100 people). Less scarring without worse hepatitis occurred in 36.8% vs 22.4% (absolute difference 14.4 percentage points; about 14 more per 100 people). Both hepatitis resolution and less scarring occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points; about 16 more per 100 people). Average weight change was -10.5% vs -2.0% (absolute difference 8.5 percentage points more weight loss). Gastrointestinal side effects were more common with semaglutide.
What this means - more context
These are absolute differences from the trial. For every 100 patients treated for 72 weeks, about 29 more had hepatitis resolution, about 14 more had reduced liver scarring, and about 16 more had both, compared with placebo. Average weight loss was about 8.5 percentage points greater with semaglutide. Absolute risks were reported directly as percentages in the study, so no extra calculation was needed.
To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3.
In this phase 3 randomized trial, once-weekly semaglutide 2.4 mg improved liver histology in patients with MASH and fibrosis stage 2 or 3 over 72 weeks. Resolution of steatohepatitis without worsening fibrosis occurred in 62.9% with semaglutide vs 34.3% with placebo (absolute difference 28.7 percentage points), and reduction in fibrosis without worsening steatohepatitis in 36.8% vs 22.4% (absolute difference 14.4 percentage points). Combined resolution and fibrosis reduction occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points). Mean weight loss was greater with semaglutide (-10.5% vs -2.0%; absolute difference -8.5 percentage points). Gastrointestinal adverse events were more common. Note: this study has published corrections/errata; readers should check correction notices for updated information.
Methods Used
Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 were assigned 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks. Planned interim analysis at week 72 involved the first 800 patients. Primary endpoints were resolution of steatohepatitis without worsening liver fibrosis and reduction in liver fibrosis without worsening steatohepatitis.
Main Finding
At 72 weeks, semaglutide 2.4 mg caused resolution of steatohepatitis without worsening fibrosis in 62.9% vs 34.3% with placebo (absolute difference 28.7 percentage points; 95% CI 21.1-36.2; P<0.001), and reduction in fibrosis without worsening steatohepatitis in 36.8% vs 22.4% (absolute difference 14.4 percentage points; 95% CI 7.5-21.3; P<0.001). Combined resolution of steatohepatitis and reduction in fibrosis occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points; 95% CI 10.2-22.8; P<0.001). Mean body weight change was -10.5% with semaglutide vs -2.0% with placebo (estimated absolute difference -8.5 percentage points; 95% CI -9.6 to -7.4; P<0.001). Gastrointestinal adverse events were more common with semaglutide.
Confidence Level
High: phase 3, multicenter, randomized, double-blind, placebo-controlled trial with large sample, pre-registered analysis, P values and confidence intervals reported. Caveats include industry funding by Novo Nordisk, interim analysis at 72 of 240 weeks, and published corrections/errata.
Study Flags
Red Flags
- •Industry funded by Novo Nordisk; several authors are Novo Nordisk employees.
- •Results are from a planned interim analysis at 72 weeks of a 240-week trial; long-term outcomes are pending.
- •Published corrections/errata exist; check the correction notices for updated information.
Surprising Findings
Bodily pain scores did not differ significantly between groups despite large weight loss.
Weight loss often improves joint pain, especially in obesity-related osteoarthritis; here no significant difference at 72 weeks.
Practical Takeaways
If you have MASH with fibrosis stage 2–3, ask your doctor about semaglutide 2.4 mg weekly as a potential treatment option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 588 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a big experiment where some people get a new medicine and some get a fake pill, and we compare them. Because the groups were chosen by chance and no one knew who got the real medicine, we can be very sure that the medicine caused the improvements in the liver. So we can say 'the medicine helps' not just 'it might help'.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized, double-blind, placebo-controlled design
- Adequate sample size (800 patients in interim analysis)
- Biopsy-confirmed diagnosis with standardized histologic endpoints
Weaknesses
- Interim analysis (part 1 of ongoing trial) may overestimate or underestimate effects
- Long-term safety and efficacy data not yet available beyond 72 weeks
- Sponsored by the drug manufacturer (Novo Nordisk) – potential for funding bias
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This large randomized trial tested weekly semaglutide 2.4 mg in people with MASH, a serious fatty liver disease, and liver scarring. Over 72 weeks, semaglutide improved liver health more than placebo and led to more weight loss. Stomach and gut side effects were more common with semaglutide. The study also has published corrections/errata, so check the notices for updated information.
Research results
In people with MASH and liver scarring: hepatitis resolution without worse scarring occurred in 62.9% with semaglutide vs 34.3% with placebo (absolute difference 28.7 percentage points; about 29 more per 100 people). Less scarring without worse hepatitis occurred in 36.8% vs 22.4% (absolute difference 14.4 percentage points; about 14 more per 100 people). Both hepatitis resolution and less scarring occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points; about 16 more per 100 people). Average weight change was -10.5% vs -2.0% (absolute difference 8.5 percentage points more weight loss). Gastrointestinal side effects were more common with semaglutide.
What this means - more context
These are absolute differences from the trial. For every 100 patients treated for 72 weeks, about 29 more had hepatitis resolution, about 14 more had reduced liver scarring, and about 16 more had both, compared with placebo. Average weight loss was about 8.5 percentage points greater with semaglutide. Absolute risks were reported directly as percentages in the study, so no extra calculation was needed.
To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3.
In this phase 3 randomized trial, once-weekly semaglutide 2.4 mg improved liver histology in patients with MASH and fibrosis stage 2 or 3 over 72 weeks. Resolution of steatohepatitis without worsening fibrosis occurred in 62.9% with semaglutide vs 34.3% with placebo (absolute difference 28.7 percentage points), and reduction in fibrosis without worsening steatohepatitis in 36.8% vs 22.4% (absolute difference 14.4 percentage points). Combined resolution and fibrosis reduction occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points). Mean weight loss was greater with semaglutide (-10.5% vs -2.0%; absolute difference -8.5 percentage points). Gastrointestinal adverse events were more common. Note: this study has published corrections/errata; readers should check correction notices for updated information.
Methods Used
Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 were assigned 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 240 weeks. Planned interim analysis at week 72 involved the first 800 patients. Primary endpoints were resolution of steatohepatitis without worsening liver fibrosis and reduction in liver fibrosis without worsening steatohepatitis.
Main Finding
At 72 weeks, semaglutide 2.4 mg caused resolution of steatohepatitis without worsening fibrosis in 62.9% vs 34.3% with placebo (absolute difference 28.7 percentage points; 95% CI 21.1-36.2; P<0.001), and reduction in fibrosis without worsening steatohepatitis in 36.8% vs 22.4% (absolute difference 14.4 percentage points; 95% CI 7.5-21.3; P<0.001). Combined resolution of steatohepatitis and reduction in fibrosis occurred in 32.7% vs 16.1% (absolute difference 16.5 percentage points; 95% CI 10.2-22.8; P<0.001). Mean body weight change was -10.5% with semaglutide vs -2.0% with placebo (estimated absolute difference -8.5 percentage points; 95% CI -9.6 to -7.4; P<0.001). Gastrointestinal adverse events were more common with semaglutide.
Confidence Level
High: phase 3, multicenter, randomized, double-blind, placebo-controlled trial with large sample, pre-registered analysis, P values and confidence intervals reported. Caveats include industry funding by Novo Nordisk, interim analysis at 72 of 240 weeks, and published corrections/errata.
Study Flags
Red Flags
- •Industry funded by Novo Nordisk; several authors are Novo Nordisk employees.
- •Results are from a planned interim analysis at 72 weeks of a 240-week trial; long-term outcomes are pending.
- •Published corrections/errata exist; check the correction notices for updated information.
Surprising Findings
Bodily pain scores did not differ significantly between groups despite large weight loss.
Weight loss often improves joint pain, especially in obesity-related osteoarthritis; here no significant difference at 72 weeks.
Practical Takeaways
If you have MASH with fibrosis stage 2–3, ask your doctor about semaglutide 2.4 mg weekly as a potential treatment option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 588 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study is like a big experiment where some people get a new medicine and some get a fake pill, and we compare them. Because the groups were chosen by chance and no one knew who got the real medicine, we can be very sure that the medicine caused the improvements in the liver. So we can say 'the medicine helps' not just 'it might help'.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized, double-blind, placebo-controlled design
- Adequate sample size (800 patients in interim analysis)
- Biopsy-confirmed diagnosis with standardized histologic endpoints
Weaknesses
- Interim analysis (part 1 of ongoing trial) may overestimate or underestimate effects
- Long-term safety and efficacy data not yet available beyond 72 weeks
- Sponsored by the drug manufacturer (Novo Nordisk) – potential for funding bias
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was very well done – it had many people, it was fair (random assignment), and both the patients and doctors were kept in the dark about who got the medicine. That means we can trust the results a lot. However, it's only part of a larger study, so we still need to see the final results to be completely sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
100 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=800)+19.6/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 588 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. As an individual RCT with narrow confidence intervals, this study can establish that semaglutide causes improvement in liver histology (resolution of steatohepatitis and fibrosis reduction) in the studied population. However, causation is limited to the specific population (MASH with fibrosis stage 2 or 3) and is based on an interim analysis at 72 weeks; final results may differ slightly.
No Conflicts
No conflicts of interest identified
No conflicts of interest declared or identified in the provided text.
The text is a scientific review article without any disclosure of conflicts of interest or funding sources. The analysis is based solely on the provided text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Strong evidence
At least some randomized or controlled trials support this claim.
Evidence
Authored by
10 researchersIf this is your work, this is how we attribute it on Fit Body Science. Philip N. Newsome is listed as the lead author.